Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.

Abstract

Follicular lymphoma has a chronic clinical course with an overall survival of 80% at 10 years, justifying its classification as an indolent B-cell lymphoma. 1 Batlevi CL Sha F Alperovich A et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020; 10: 74 Google Scholar Unfortunately, follicular lymphoma is a heterogenous disease, and about one in five patients relapses within 2 years after the start of initial treatment. 2 Casulo C Byrtek M Dawson KL et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study. J Clin Oncol. 2015; 33: 2516-2522 Google Scholar Furthermore, retrospective data have shown that progression-free survival and overall survival substantially decrease in the relapsed setting, reflecting the clinical experience that patients with follicular lymphoma become more treatment-resistant in later lines of therapy. 1 Batlevi CL Sha F Alperovich A et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020; 10: 74 Google Scholar Thus, despite the generally indolent nature of follicular lymphoma, a great unmet medical need exists for efficient treatments for patients with relapsed or refractory follicular lymphoma, and the therapeutic armamentarium for later lines of treatment is particularly scarce. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyFixed-duration mosunetuzumab has a favourable safety profile and induces high rates of complete remissions, allowing potential administration as an outpatient regimen, in patients with relapsed or refractory follicular lymphoma and two or more previous therapies. Full-Text PDF